• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Jan. 29, 2018

View Archived Issues

Bench Press: BioWorld looks at translational medicine

Kinase inhibitors are collectively one of the most successful drug classes, but they are challenging to develop in part because their activity usually depends on their overall effect on multiple different kinases. Read More

In the clinic

Astrazeneca plc, of London, said the phase III Kronos trial showed positive results for PT-010 triple combination therapy in chronic obstructive pulmonary disease (COPD). Read More

Other news to note

Multivir Inc., of San Francisco, reported that tumors shown to be resistant to anti-PD-1 therapy were made vulnerable to it when the therapy was combined with one of its immune gene therapies, Adenoviral p53 or Ad-Relaxin. Read More

Financings

Stemline Therapeutics Inc., of New York, said it closed its public offering of about 4.3 million shares of common stock, including the exercise in full of the option to purchase 555,000 additional shares, at a price of $14 per share. Read More

Lynparza, Fasenra cleared in Japan as Astrazeneca enjoys improved productivity

HONG KONG – Astrazeneca plc has received approval for two drug candidates – PARP inhibitor Lynparza (olaparib) and IL-5 receptor targeting Fasenra (benralizumab) – from the Japanese Ministry of Health, Labour and Welfare, the latest sign of the big pharma's recent improvement in productivity following its 2011 overhaul. Read More

Insights, drug candidates for K-Ras-driven cancers

Separate research teams offered insight this week into how Ras-driven pancreatic cancers develop, and reported that a small molecule targeting mutated K-Ras led to tumor regression in patient-derived xenograft mouse models of K-Ras-driven cancers. Read More

Hospitals seek not-for-profit solution for troubled generic drug market

Talk with the administrators of any given U.S. hospital system, and you'll hear their frustration over shortages of essential medications developed in the 1950s, '60s and '70s – long off-patent – plaguing the U.S. health care system. Read More

Solid soldiers on to $125M IPO after filing 'kerfuffle'

It's been a heady January for biopharma financings, but talk of frothy markets is certain to escalate after Solid Biosciences Inc. salvaged its offering with some fancy footwork, pricing 7.8 million common shares at $16 apiece to gross $125 million. Solid, of Cambridge, Mass., originally planned to offer 5.9 million shares priced in a range of $16 to $18, setting its sights on a raise of about $100 million. Read More

CHMP nods through seven products at monthly meeting

DUBLIN – Merck & Co. Inc., Roche Holding AG, Chiesi Farmaceutici SpA and Glaxosmithkline plc entered the winners' enclosure following the monthly meeting of the EMA's Committee for Human Medicinal Products (CHMP) in London this week. Read More

AAA in tow, Novartis wins Lutathera NET bet at FDA; CRL chains loosen easily

Friday's approval of the resubmitted NDA for Lutathera (lutetium [177Lu] oxodotreotide) stands as proof that issues raised by a complete response letter (CRL) "were really on technical problems," Stefan Buono, former CEO of Advanced Accelerator Applications SA (AAA), told BioWorld. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe